Intravitreal aflibercept for diabetic macular oedema in real-world: 36-month visual acuity and anatomical outcomes
International Journal of Development Research
Intravitreal aflibercept for diabetic macular oedema in real-world: 36-month visual acuity and anatomical outcomes
Received 27th March, 2021; Received in revised form 20th April, 2021; Accepted 06th May, 2021; Published online 20th June, 2021
Copyright © 2021, Dan Călugăru and Mihai Călugăru. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
The authors are commenting on the study entitled: “Intravitreal aflibercept for diabetic macular oedema in real-world: 36-month visual acuity and anatomical outcomes” published by Lukic et al. in European Journal Ophthalmology 2020 (Doi: 10.1177/1120672120925034. Published on May 19, 2020), which assessed structural and functional outcomes of treatment with aflibercept for centre-involving diabetic macular oedema in 57 patients (64 eyes) with diabetes. The authors concluded that there was a significant improvement in visual acuity and in anatomical outcomes in aflibercept-treated eyes at 36 months after commencing treatment for diabetic macular oedema in real-life settings. However, the validation, extrapolation, and generalizabilty of these findings can only be made by statistical analyses including all the missing baseline potential risk factors referred to above by us in addition to the baseline characteristics already evaluated in this study, serving to emphasize the key metrics assessing the efficacy of intravitreal aflibercept for diabetic macular oedema in patients with diabetes mellitus.
